Why the study?
Does reteplase reduce 30-day mortality compared to alteplase in patients with acute myocardial infarction complicated by cardiogenic shock?
Population
820 patients with acute myocardial infarction who presented with or developed cardiogenic shock
Comparison
Reteplase (two bolus doses of 10 MU, 30 min apart) vs Front-loaded alteplase
Design
RCT, randomized
Follow-up
30 days
Authors
Loading...
Reteplase confers no mortality benefit over alteplase in AMI shock; confirms similar outcomes and supports either agent.
Does reteplase reduce 30-day mortality compared to alteplase in patients with acute myocardial infarction complicated by cardiogenic shock?
Reteplase does not improve 30-day mortality compared to alteplase in patients with acute myocardial infarction complicated by cardiogenic shock.
David Hasdai (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: